ClinicalTrials.gg
RecruitingNCT06559215Updated Mar 9, 2026

Evaluation of Pain Management After Surgery When Using Exparel in the Pediatric Population

A Phase 2 interventional study of Exparel in Medial Patellofemoral Ligament (MPFL) Reconstruction, Sports Injuries in Children and Analgesia, sponsored by Texas Scottish Rite Hospital for Children. Recruiting at 1 site in United States. Open to participants aged 13 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Texas Scottish Rite Hospital for Children · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
13 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Planned enrollment
33rd of 93
100 · median 80
Started
2025
with 2 others
Phase 2
8 of 93
2 open now
Primary completion
2027-09
later than 11 of 14 live
Registered
88th of 93
by date

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 33rd largest by planned enrollment, is one of 3 that started in 2025, is one of 8 in phase 2, reaches primary completion later than 11 of the 14 other live ones, and was the 88th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 13 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial is to determine if administration of Exparel via local infiltration for medial patellofemoral ligament (MPFL) reconstruction procedures in pediatric orthopaedic sports medicine patients provides significant pain relief and decreased narcotic use. The main questions it aims to answer are:

  • Does Exparel significantly reduce Visual Analog Scale (VAS) pain scores and pain levels up to one week postoperatively?
  • Does Exparel significantly decrease narcotic use (number of pills taken) up to one week postoperatively?

Researchers will compare the pain outcomes and narcotic use of patients who receive Exparel and Marcaine via local infiltration to those of patients who receive only Marcaine via local infiltration for their MPFL reconstruction surgery. The goal is to understand if there is a significant difference in patient pain outcomes and narcotic use outside the first 24 hours postoperatively.

Participants will:

  • receive either Exparel + Marcaine intraoperatively or Marcaine only intraoperatively during their MPFL reconstruction surgery
  • receive and complete questionnaires at postoperative days 1, 4, and 7 regarding their pain scores, levels, and outcomes, effective pain treatments, overall pain interference, narcotic use (number of pills taken), and overall pain treatment satisfaction
  • receive and complete secondary outcome measures of functional and psychological outcomes regarding their MPFL reconstruction surgery at postoperative day 1
Read the detailed description

This is a single institution, prospective, single-blinded (patient) randomized controlled trial to investigate the pain-control efficacy and patient reported pain outcomes of Exparel use in youth receiving MPFL Reconstruction. Participants will be randomized into two groups, Exparel + Marcaine or Marcaine-only. To be included, participants must be aged 10+ years at the time of surgery and present with an injury requiring an isolated MPFL reconstruction. Data will be collected from the patient's electronic medical record and from Oberd. Data collected will include age, height, weight, surgical information, diagnosis, patient reported outcomes (PROs) and patient demographics. 100 participants (50 per treatment group) will be enrolled in the study with a minimum of 80 needed to complete the study. Patients will be approached pre-operatively for participation, after which the surgical team will be informed. Patients will be offered the choice to participate in the study and randomize their treatment group. If patients do not want their treatment to be randomized, they will not be included in the study. Data collection will involve the Wong-Baker Visual Analog Scale (VAS) and VAS 10-centimeter line 0-10 Numeric Pain Intensity Scale, and an institution specific pain questionnaire regarding analgesic medicine intake and complications at postoperative day one, four and seven. A pain management patient satisfaction questionnaire will also be administered on post-operative day seven. Patients' medical records will also be reviewed for readmission, calls to their physician for pain, and other noted complications.

Patients will receive the following anesthesia doses by body weight (BW):

Pre-operatively:

  • Regardless of age: 0.5 mg Midazolam per kg BW (intravenous, 15 mg maximum)
  • If patient has history of PONV, 0.40 mg Emend per kg BW (pill), and 2 mg Midazolam (intravenous), and/or Scopolamine patch
  • If patient has history of anxiety or PTSD, or exhibits anxiety symptoms before surgery: 0.1 mg Valium per kg BW (maximum 10 mg)

Intra-operatively:

  • Amounts discretionary by patient vitals 0.5-1.0 mg Lidocaine per kg BW (intravenous -- no maximum) 3-4 mg Propofol per kg BW (no maximum) 1-2 mcg Fentanyl per kg BW (no maximum) 0.35 mg Ketamine per kg BW (no maximum) 0.1 mg Dexamethasone per kg BW (no maximum) If necessary: 0.004 - 0.006 mg Hydromorphone per kg BW (no maximum)
  • Optional:

10-20 mcg Dexmedetomidine per kg BW (for persistent tachycardia) \<50% Nitrous If intubated/ventilated: 0.5-0.6 mg Rocuronium per kg BW, \~2 mg/kg Sugammadex for reversal If Tranexamic Acid administered: 15 mg per kg BW (10-15 min intravenous, maximum 1 g) For maintenance: 1 Minimum Alveolar Concentration (MAC) Sevoflurane and 15 mg Acetaminophen per kg BW (maximum 1 g) If necessary during emergence: 0.004-0.005 mg Hydromorphone per kg BW, 0.5 mg Ketorolac per kg BW (maximum 30 mg), and 0.1 mg Ondansetron per kg BW (maximum 4 mg)

- If PACU medication required: 0.004-0.006 mg Hydromorphone per kg BW and 0.10- 0.15 mg Oxycodone per kg BW, and Metoclopramide, Dexamethasone, Promethazine, or Ondansetron

Exparel + Marcaine Group:

- Local Infiltration: Regardless of weight: 10 mL Exparel and 10 mL 0.25% Marcaine

Marcaine Only Group:

- Local Infiltration: Regardless of weight: 20 mL 0.25% Marcaine

Post-Operatively:

  • Days 1-3: Alternate weight-adjusted Acetaminophen and 10 mg Ketorolac every 3 hours
  • Days 4-7: Alternate weight-adjusted Acetaminophen and Ibuprofen every 3 hours
  • Days 1-5: 40 mg Famotidine every 12 hours
  • Rescue: Weight-adjusted Tramadol taken with Acetaminophen for severe pain (every 6 hours, maximum 8 doses) The investigators will enroll 50 patients in each treatment group with 40 in each group needed for a sufficiently powered analysis. Patients will not be informed of their treatment group until after the study is complete.
03

Conditions studied

  • Medial Patellofemoral Ligament (MPFL) Reconstruction
  • Sports Injuries in Children
  • Analgesia
  • Pain, Postoperative

Browse trials for

Keywords

  • Narcotic use
  • Postoperative pain management
  • MPFL reconstruction
  • Visual Analog Scale (VAS) pain scores
  • Multimodal pain management protocol
04

Who can participate

Ages eligible
13 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be aged 13+ years at time of surgery
  • Must present with injury requiring an isolated MPFL Reconstruction
  • Ability to provide assent, legally appointed representative available to provide

Exclusion criteria

Exclusion Criteria:

  • Patient \<13 years old
  • Requires fracture repair or another non-standardized surgery
  • Any MPFL Reconstruction that requires the use of arthrotomy or a tibial tubercle osteotomy
  • Any lower extremity procedure that is not an isolated MPFL Reconstruction
  • Patient pregnancy
  • Inability to provide assent or legally appointed representative to provide
  • Prior history of to Exparel or any local anesthesia
  • ≥ 40
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Exparel + Marcaine Group

    Local Infiltration: Regardless of weight: 10 mL Exparel and 10 mL 0.25% Marcaine

    Drug: Exparel

  • No intervention
    Marcaine Only Group

    Local Infiltration: Regardless of weight: 20 mL 0.25% Marcaine

Interventions

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS) Wong-Baker Face Pain Scale

    Scale with evocative faces from 0-10 (0 = No Pain, 10 = Worst Pain Possible) that assists children in communicating about their pain

    Time frame: Postoperative days 1, 4, and 7

  2. Visual Analog Scale (VAS) 10-centimeter line 0-10 Numeric Pain Intensity Scale

    Sliding scale from 0-10 (0 = No Pain, 10 = Pain as bad as it could possibly be) that enables a more accurate estimate of pain score

    Time frame: Postoperative days 1, 4, and 7

  3. Scottish Rite for Children-developed pain questionnaire

    Institutional questionnaire that asks how many narcotic pills the patient has taken (0 - 12 pills), if their pain is controlled, treatments that lessens their pain, term that best describes their pain, how much their pain has interfered with daily tasks and overall mood, and sleep interference due to pain.

    Time frame: Postoperative days 1, 4, and 7

  4. Pain Management Patient Satisfaction questionnaire

    Questionnaire that asks how satisfied patients are with their pain treatment (0 = Not Satisfied, 10 = Extremely Satisfied), if they contacted their physician due to ineffective pain treatment, how helpful the information provided for pain treatment was (0 = Not Helpful, 10 = Extremely Helpful), and a free response section to explain why they were not satisfied with their pain treatment and if they have any additional comments or suggestions based on their pain treatment.

    Time frame: Postoperative day 7

Secondary outcomes

  1. Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Scale v1.0 - Global Health 7+2

    Questionnaire of outcomes regarding their overall health (scored 20-80, 20 = poor and 80 = good).

    Time frame: Preoperatively and within one week postoperatively

07

Study locations

1 of 1 sites recruiting
  • Texas Scottish Rite Hospital for Children
    Frisco, Texas 75034, United States
    Recruiting
    • Robert Van Pelt, MPH · Contactbobby.vanpelt@tsrh.org · 214-559-7456
    • Anna Wilhelmy, MS · Contactanna.wilhelmy@tsrh.org · 469-857-2109
    • Philip Wilson, MD · Principal investigator
    • Henry Ellis, MD · Sub investigator
    • John Arvesen, MD · Sub investigator
    • Cody Todesco, PA · Sub investigator
    • Benjamin Johnson, PA · Sub investigator
    • Charles Wyatt, CPNP · Sub investigator
    • Stephanie Stutz, MS · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 90 non-industry phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 21 months is above that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2024
First posted
Aug 19, 2024
StartActual
Dec 1, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06559215
Lead sponsor
Texas Scottish Rite Hospital for Children
Responsible party
Sponsor
First posted
Aug 19, 2024
Start date
Dec 1, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Mar 9, 2026

Study contacts

Robert Van Pelt, MPH
Contact
bobby.vanpelt@tsrh.org
2145597456
Anna Wilhelmy, MS
Contact
anna.wilhelmy@tsrh.org
469-857-2109
Philip Wilson, MD
principal investigator · Texas Scottish Rite Hospital for Children

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion